title: [New molecular targeting drugs for metastatic colorectal cancer].
abstract: I explain an outline of the molecular target of new drugs for colorectal cancer. First, regorafenib is an orally active, multikinase inhibitor. Second, as angiogenesis inhibitors, aflibercept and ramucirumab. Aflibercept is the second anti-angiogenic agent after bevacizumab with a FDA approval for metastatic colorectal cancer. Ramucirumab is a fully human mAb that binds human VEGFR-2, thus blocking VEGF binding and inhibiting angiogenesis. Finally, I introduce a new combination chemotherapy regimen with molecular targetting drugs.
authors.affiliation: Hokkaido University Hospital Cancer Center.
authors.forename: Yoshito
authors.initials: Y
authors.lastname: Komatsu
authors.affiliation: Hokkaido University Hospital Cancer Center.
authors.forename: Kazuaki
authors.initials: K
authors.lastname: Harada
authors.affiliation: Hokkaido University Hospital Cancer Center.
authors.forename: Hiraku
authors.initials: H
authors.lastname: Fukushima
authors.affiliation: Hokkaido University Hospital Cancer Center.
authors.forename: Satoshi
authors.initials: S
authors.lastname: Yuki
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D058990:Molecular Targeted Therapy; D009362:Neoplasm Metastasis; D010671:Phenylurea Compounds / Q000627:therapeutic use; D011725:Pyridines / Q000627:therapeutic use; D040262:Receptors, Vascular Endothelial Growth Factor / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D000096662:Ramucirumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D010671:Phenylurea Compounds; D011725:Pyridines; D040262:Receptors, Vascular Endothelial Growth Factor; D011993:Recombinant Fusion Proteins; D000096662:Ramucirumab; C533178:aflibercept; C559147:regorafenib